Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review (Q38857820)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

Europe PubMed Central

Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Emilio Martin-Mola

1

object named as

Emilio Martin-Mola

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

author name string

Alejandro Balsa

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Rosario García-Vicuna

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Juan Gómez-Reino

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Miguel Angel González-Gay

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Estíbaliz Loza

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

publication date

6 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Rheumatology International

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1043-1063

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

The prevalence of rheumatoid arthritis in the general population of Spain.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Adaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rituximab for rheumatoid arthrits treatment: a systematic review.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Anti-keratin antibodies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Use and significance of anti-CCP autoantibodies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The influence of ACPA status and characteristics on the course of RA.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the 'AMC-Senshu' method

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Citrullination of synovial proteins in murine models of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The presence of citrullinated proteins is not specific for rheumatoid synovial tissue

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

A prediction rule for the development of arthritis in seropositive arthralgia patients

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Smoking and overweight determine the likelihood of developing rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

HLA class II association with rheumatoid arthritis: facts and interpretations

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Genes, environment and immunity in the development of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis: modifiable risk factors?

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Arthritis and bone loss: a hen and egg story

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid arthritis: a disease associated with accelerated atherogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Accelerated atherosclerosis in autoimmune rheumatic diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Atherosclerotic cardiovascular disease in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: Two faces of the same coin

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Osteoprotegerin concentrations relate independently to established cardiovascular disease in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Accelerated atherosclerosis in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Carotid Intima-Media Thickness Predicts the Development of Cardiovascular Events in Patients with Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Predictors of response to TNF antagonists.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Immunotherapeutic implication of IL-6 blockade

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Abatacept use in rheumatoid arthritis: evidence review and recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Differences in synovial tissue infiltrates between anti–cyclic citrullinated peptide–positive rheumatoid arthritis and anti–cyclic citrullinated peptide–negative rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis a

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3506-3

21 January 2018

The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab therapy in Greek patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Genetics of rheumatoid arthritis]

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of anticyclic citrullinated peptide antibodies, interleukin-6, tumor necrosis factor-α, and C-reactive protein are associated with increased carotid intima-media thickness: a cross-sectional analysis of a cohort of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The joy of citrulline: new insights into the diagnosis, pathogenesis, and treatment of rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum anti-cyclic citrullinated peptide antibodies may predict disease activity in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiperinuclear factor: a useful test for the diagnosis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiperinuclear factor as a prognostic marker in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B lymphocyte depletion in rheumatoid arthritis: targeting of CD20

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis--a systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second generation automated anti-CCP test better predicts the clinical diagnosis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27271502

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00296-016-3506-3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38857820&oldid=2202187490"